Search Results
Search for other papers by Yiyun Cui in
Google Scholar
PubMed
Search for other papers by Jinlong Chen in
Google Scholar
PubMed
Search for other papers by Rui Guo in
Google Scholar
PubMed
Search for other papers by Ruize Yang in
Google Scholar
PubMed
Search for other papers by Dandan Chen in
Google Scholar
PubMed
Search for other papers by Wei Gu in
Google Scholar
PubMed
Search for other papers by Francis Manyori Bigambo in
Google Scholar
PubMed
Search for other papers by Xu Wang in
Google Scholar
PubMed
remission and relapse groups on admission. Reference ranges Remission group ( n = 39) Relapse group ( n = 40) P ALT (U/L) 5–40 25.00 (19.00–37.00) 28.50 (21.75–37.50) 0.50 AST (U/L) 5–40 25.00 (20
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK
Search for other papers by Claire L Wood in
Google Scholar
PubMed
Search for other papers by Niamh Morrison in
Google Scholar
PubMed
Search for other papers by Michael Cole in
Google Scholar
PubMed
Search for other papers by Malcolm Donaldson in
Google Scholar
PubMed
Wellcome Trust-MRC Institute of Metabolic Sciences, University of Cambridge, Cambridge, UK
Search for other papers by David B Dunger in
Google Scholar
PubMed
Search for other papers by Ruth Wood in
Google Scholar
PubMed
Department of Endocrinology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
Search for other papers by Simon H S Pearce in
Google Scholar
PubMed
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK
Search for other papers by Timothy D Cheetham in
Google Scholar
PubMed
thyroxine (FT4) response in the two groups; specifically the time taken for TSH levels to rise or for FT4 concentrations to fall within the local reference ranges. Free tri-iodothyroinine (FT3) concentrations were not measured routinely in this trial
Institute of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Search for other papers by Peter F Berglund in
Google Scholar
PubMed
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Göteborg, Sweden
Gothenburg Centre for Person Centred-Care (GPCC), Göteborg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
Hospital, Göteborg ( n = 64) and from the Department of Medicine at Kungälv’s Hospital, Kungälv ( n = 1) in Sweden. They were eligible for the study if they were premenopausal, with fT4 levels ≥50 pmol/L (reference range: 12–22) and/or total T3 ≥6.0 nmol
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Laura Pierotti in
Google Scholar
PubMed
Search for other papers by Nicola Viola in
Google Scholar
PubMed
Search for other papers by Isabella Lupi in
Google Scholar
PubMed
Search for other papers by Lucia Montanelli in
Google Scholar
PubMed
Search for other papers by Chiara Cremolini in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Antonio Chella in
Google Scholar
PubMed
Search for other papers by Andrea Antonuzzo in
Google Scholar
PubMed
Search for other papers by Daniele Sgrò in
Google Scholar
PubMed
Search for other papers by Lucia Antonangeli in
Google Scholar
PubMed
Search for other papers by Chiara Sardella in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Ferruccio Santini in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
). Reference ranges were 8–18 ng/dL for FT4, 2.5–5.0 ng/L for FT3 and 0.4–4 mIU/L for TSH. Tg was measured by an immunometric assay (Access Thyroglobulin assay; Beckman Coulter, Inc., Fullerton, CA, USA) (functional sensitivity 0.1 ng/mL). TgAbs were measured
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by J Karmisholt in
Google Scholar
PubMed
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by S L Andersen in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by I Bulow-Pedersen in
Google Scholar
PubMed
Search for other papers by A Krejbjerg in
Google Scholar
PubMed
Search for other papers by B Nygaard in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by A Carlé in
Google Scholar
PubMed
, agranulocytosis, and liver failure. Thyroid hormone and antibody assays Serum total T3 (reference range: Aalborg 1.1–2.5 nmol/L, Copenhagen 1.0–2.6 nmol/L), and TSH (reference range: Aalborg 0.30–4.5mU/L, Copenhagen 0.40–4.0 mU/L) were measured by automatic
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Department of Pedagogical, Curricular and Professional Studies, Faculty of Education, University of Gothenburg, Gothenburg, Sweden
Search for other papers by Simon Skau in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
was 4.0 months. Inclusion criteria were as follows: (i) premenopausal, (ii) free thyroxine ≥ 50 pmol/L (reference range 12–22) and/or total triiodothyronine ≥ 6.0 pmol/L (reference range 1.3–3.1), and (iii) positive thyroid-stimulating hormone
Search for other papers by Ringo Manta in
Google Scholar
PubMed
Search for other papers by Charlotte Martin in
Google Scholar
PubMed
Search for other papers by Vinciane Muls in
Google Scholar
PubMed
Search for other papers by Kris G Poppe in
Google Scholar
PubMed
Reference range Year 2020 Year 2021 March 23 April 7 April 9 June 22 August 5 December 7 February 2 March 18 a April 12 April 14 April 27 Thyrotropin (mIU/L) 0.27–4.20 5.42 7.36 2.86 1.35 3.21 2/29 1
Search for other papers by Georgios Kostopoulos in
Google Scholar
PubMed
Search for other papers by Grigoris Effraimidis in
Google Scholar
PubMed
subclinical hyperthyroidism and FT4 within the normal reference range. Study Year Country Design Subjects, n Age, years FU, years Thyroid function AF, % Risk (95% CI) Overt hyperthyroidism Selmer
Search for other papers by Sébastien Verdickt in
Google Scholar
PubMed
Search for other papers by Falco Van Nes in
Google Scholar
PubMed
Search for other papers by Carolien Moyson in
Google Scholar
PubMed
Search for other papers by Toon Maes in
Google Scholar
PubMed
Search for other papers by Paul Van Crombrugge in
Google Scholar
PubMed
Search for other papers by Annick Van den Bruel in
Google Scholar
PubMed
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
euthyroidism defined as TSH and fT4 within the normal reference range in a patient not synchronously treated with ATDs or L-T4. Hyperthyroidism was defined as either not meeting the criteria of cure or having undergone thyroid surgery or having received a
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine and School of Medicine, Seoul, Republic of Korea
Search for other papers by Meihua Jin in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea
Search for other papers by Ahreum Jang in
Google Scholar
PubMed
Search for other papers by Chae A Kim in
Google Scholar
PubMed
Search for other papers by Tae Yong Kim in
Google Scholar
PubMed
Search for other papers by Won Bae Kim in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
measured by RIA using T3-CTK (DiaSorin SpA). The reference ranges of TSH, fT4, and total T3 were 0.4–4.5 mIU/L, 0.80–1.90 ng/dL, and 151–277 ng/dL, respectively. TRAb was measured using a competitive TSH-binding inhibitory immunoglobulin (TBII) assay by the